Setmelanotide
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity
Rhythm · Phase 2 · Completed · Enrollment 213
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| 16p11.2 Cohort | Obesity or overweight | n/r | 16 | n/r | n/r |
| AS Cohort | Obesity or overweight | n/r | 16 | n/r | n/r |
| BBS Cohort | Obesity or overweight | n/r | 16 | n/r | n/r |
| MC4R Cohort | Obesity or overweight | n/r | 16 | n/r | n/r |
| POMC/PCSK1/LEPR Heterozygous Cohort | Obesity or overweight | n/r | 16 | n/r | n/r |
| POMC/PCSK1/LEPR Composite Heterozygous Cohort | Obesity or overweight | n/r | 16 | n/r | n/r |
| POMC/PCSK1/LEPR Compound Heterozygous Cohort | Obesity or overweight | n/r | 16 | n/r | n/r |
| SH2B1 Cohort | Obesity or overweight | n/r | 16 | n/r | n/r |
| SMS Cohort | Obesity or overweight | n/r | 16 | n/r | n/r |
| SRC1 Cohort | Obesity or overweight | n/r | 16 | n/r | n/r |